<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-two patients with untreated ALL (n = 26) or lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 6) between 17 and 65 years of age were treated with a short remission induction course with <z:chebi fb="0" ids="4911">VP16</z:chebi>-213, <z:chebi fb="0" ids="2687">amsacrine</z:chebi>, intermediate dose Ara-C for 6 days, <z:chebi fb="0" ids="8382">prednisone</z:chebi> and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, followed by a consolidation course with <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="2687">amsacrine</z:chebi>, high dose Ara-C for 4 days, <z:chebi fb="0" ids="8382">prednisone</z:chebi> and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>After subsequent cranial irradiation, no further maintenance was planned </plain></SENT>
<SENT sid="2" pm="."><plain>However, some patients underwent an allogenic (n = 5) or autologous (n = 5) bone marrow transplantation after the consolidation treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-three of 32 patients (72%) achieved a complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>Ten of 13 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> or <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, six of eight patients with pre-B or <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">common ALL</z:e>, and seven of 11 patients with <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> or Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> achieved a complete remission </plain></SENT>
<SENT sid="5" pm="."><plain>The median duration of remission was 24 months </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival for the whole group was 35% at 5 years </plain></SENT>
<SENT sid="7" pm="."><plain>The disease-free survival was 45% at 5 years </plain></SENT>
<SENT sid="8" pm="."><plain>Long-term survival for patients with B or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> was approximately 60%, compared with 15% for those with common or <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre B-ALL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Short term intensive courses including intermediate or high dose Ara-C during remission and consolidation treatment lead to results comparable to those obtained with long-term maintenance regimens </plain></SENT>
<SENT sid="10" pm="."><plain>Our regimen may be sufficient for patients with T or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Larger randomized studies are needed to investigate the relative importance of our observations </plain></SENT>
</text></document>